Case Study 3: Incorporating Patient-Reported Outcomes in Your Practice to Achieve Wellness in Rheumatoid Arthritis CME

Author Information and Disclosures

Release Date: June 24, 2008; Valid for credit through June 24, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This CME program was created for use on eMedicine.com.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of education | outcomes | science.This CME activity is provided by education | outcomes | science solely for educational purposes. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Copyright © 2008 education | outcomes | science
Bristol-Myers Squibb
Learning Objectives

Upon completion of this activity, participants should be better able to:

  1. Discuss the therapeutic options for patients who failed therapy with either methotrexate or TNF inhibitors, based on the latest data from biologic clinical trials
  2. Identify challenges faced by clinicians when choosing a therapeutic strategy in RA
  3. Define and respond to treatment failures in practice
Authors and Disclosures

Paul Emery, MA, MD, FRCP
Disclosure: Dr. Emery: Speaker: Abbott Laboratories, Amgen, Bristol-Myers Squibb, Centocor, Merck & Co., Inc., Novartis, Pfizer Inc, Roche, Schering-Plough, UCB, Wyeth
 
education | outcomes | science
education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

education | outcomes | science designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Medical Association has determined that non-US licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 CreditTM.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.